[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

← Portfolio

HTT-Lowering ASO for Huntington Disease

Edit / manage →

Huntington disease

Phase 1ActiveAntisense oligonucleotideNeurodegenerationConcerning· medium conf3 evidence-linked claims2 snapshots

Overview

Disease area
Neurodegeneration
Indication
Huntington diseaseMONDO:0007739
Mechanism of action
Non-allele-selective huntingtin mRNA knockdown
Development stage
Phase 1
Institution
Capitol Movement Disorders Center
Principal investigators
S. Nakamura
Targets
HTT
Pathways
Huntingtin clearance
Trial registry
NCT00975481

Timeline

state through time · newest first
  1. Q3 2024Series A
    Milestones
    • ·Interim safety review passed
    Accomplishments
    • ·No neurofilament safety signal at mid dose
    Challenges
    • ·Slow enrichment of fast-progressing cohort
    Next steps
    • ·Lock Phase 2 dose
    • ·Expand CAP-score enrichment
    Risk themes:Enrollment enrichmentDose-exposure window
  2. Q2 2024Series A
    Milestones
    • ·Phase 1 multiple-ascending-dose ongoing
    Accomplishments
    • ·CSF mutant huntingtin lowering demonstrated
    Challenges
    • ·Wild-type HTT lowering raises long-term safety questions
    Next steps
    • ·Define exposure ceiling
    • ·Plan allele-selective follow-on
    Risk themes:Wild-type knockdown safetyPrior class setbacks

Scientific assessment

1 claims
  • Mechanistic RationaleModerate

    Huntingtin lowering targets the root monogenic cause; however non-allele-selective knockdown raises wild-type HTT safety questions.

    trialNCT00975481

Translational assessment

1 claims
  • Natural HistoryModerate

    CAG-repeat length and CAP score enable enrichment of fast-progressing cohorts to power shorter trials.

    publicationPMID:31302841

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

0 claims

No evidence linked yet.

Execution assessment

1 claims
  • Operational RisksLimited

    Prior late-stage HTT-lowering programs paused for futility/safety; dose and exposure strategy is the key execution risk.

    internalrisk-2024

Structured reviews

1 reviews
Concerning· medium confInternalIC review2024-09-30
Strengths

Addresses the root monogenic cause.

Weaknesses

Wild-type huntingtin lowering safety; prior class setbacks.

Improvement areas

Define exposure ceiling; consider allele-selective follow-on.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Active
    Phase 1 ongoing; exposure ceiling under evaluation.2024-07-10

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.